Skip to content
Cost Curve NewsCost Curve News
  • Home
  • About
  • News
  • Subscribe
22Jan2026
  • Home
  • About
  • News
  • Subscribe
22Jan2026
Cost Curve NewsCost Curve News
Cost Curve News

J&J Quantifies the Impact of Its MFN Concessions: ‘It’s Hundreds of Millions of Dollars’

Premium Content This content is reserved for premium subscribers of Premium Membership. To Access this and other great posts, consider upgrading to premium. UpgradeLink ConjuctionSign In Powered by beehiiv  
9 hours ago
Keep Reading
Cost Curve News

How Quickly Do Pharma Companies Update the Prices on Drug Websites?

Premium Content This content is reserved for premium subscribers of Premium Membership. To Access this and other great posts, consider upgrading to premium. UpgradeLink ConjuctionSign In Powered by beehiiv  
1 day ago
Keep Reading
Cost Curve News

All Eyes Are on MFN … But Action and Specifics Remain Elusive

Premium Content This content is reserved for premium subscribers of Premium Membership. To Access this and other great posts, consider upgrading to premium. UpgradeLink ConjuctionSign In Powered by beehiiv  
6 days ago
Keep Reading
Cost Curve News

With MFN Deals in the Rear-View Mirror, Pharma CEOs at JPM Say They Can ‘Focus More on the Fundamentals’

Premium Content This content is reserved for premium subscribers of Premium Membership. To Access this and other great posts, consider upgrading to premium. UpgradeLink ConjuctionSign In Powered by beehiiv  
1 week ago
Keep Reading
Cost Curve News

Why One Small Company — About to Take on an Industry Giant — Won’t Compete on Price

Premium Content This content is reserved for premium subscribers of Premium Membership. To Access this and other great posts, consider upgrading to premium. UpgradeLink ConjuctionSign In Powered by beehiiv  
1 week ago
Keep Reading
Cost Curve News

Six Policy Questions that J.P. Morgan Presentations May Help Answer

Premium Content This content is reserved for premium subscribers of Premium Membership. To Access this and other great posts, consider upgrading to premium. UpgradeLink ConjuctionSign In Powered by beehiiv  
1 week ago
Keep Reading
Cost Curve News

J&J Becomes Company No. 15 to Make a Deal with the White House, Though Details Remain Sparse

Premium Content This content is reserved for premium subscribers of Premium Membership. To Access this and other great posts, consider upgrading to premium. UpgradeLink ConjuctionSign In Powered by beehiiv  
2 weeks ago
Keep Reading
Cost Curve News

Will Pharma’s MFN Deals to Change the Drug-Price Reality for U.S. Patients or European Governments?

Premium Content This content is reserved for premium subscribers of Premium Membership. To Access this and other great posts, consider upgrading to premium. UpgradeLink ConjuctionSign In Powered by beehiiv  
2 weeks ago
Keep Reading
Cost Curve News

Empty Offices, Full Coffers: A Journalistic Expose Examines How PBMs Use Group Purchasing Organizations to Profit

Premium Content This content is reserved for premium subscribers of Premium Membership. To Access this and other great posts, consider upgrading to premium. UpgradeLink ConjuctionSign In Powered by beehiiv  
2 weeks ago
Keep Reading
Cost Curve News

The Most Interesting Drug Pricing News of the Year Is Flying Under the Radar

Premium Content This content is reserved for premium subscribers of Premium Membership. To Access this and other great posts, consider upgrading to premium. UpgradeLink ConjuctionSign In Powered by beehiiv  
2 weeks ago
Keep Reading
123

Latest Posts

J&J Quantifies the Impact of Its MFN Concessions: ‘It’s Hundreds of Millions of Dollars’

January 21, 2026

How Quickly Do Pharma Companies Update the Prices on Drug Websites?

January 20, 2026

All Eyes Are on MFN … But Action and Specifics Remain Elusive

January 15, 2026

With MFN Deals in the Rear-View Mirror, Pharma CEOs at JPM Say They Can ‘Focus More on the Fundamentals’

January 14, 2026

Why One Small Company — About to Take on an Industry Giant — Won’t Compete on Price

January 13, 2026

Popular

J&J Quantifies the Impact of Its MFN Concessions: ‘It’s Hundreds of Millions of Dollars’

How Quickly Do Pharma Companies Update the Prices on Drug Websites?

All Eyes Are on MFN … But Action and Specifics Remain Elusive

With MFN Deals in the Rear-View Mirror, Pharma CEOs at JPM Say They Can ‘Focus More on the Fundamentals’

Why One Small Company — About to Take on an Industry Giant — Won’t Compete on Price

Six Policy Questions that J.P. Morgan Presentations May Help Answer

Most Viewed
  • CMS Patient-Focused Listening Session Transcripts (3,130)
  • New JAMA Research Shows How Much — and How Rapidly — Part D Plans Have Shifted Drug Costs to Consumers (2,329)
  • Working Out the Strange Math and Weird Consequences of IRA Inflation Penalties (2,052)
  • More IRA Lawsuits Coming, PhRMA Chief Predicts (1,859)
  • Bernie Sanders Wants to Talk to CEOs About US vs ROW Pricing. Bring It On, I Say. (1,848)

Your trusted source for daily updates on drug pricing and policy. Stay informed and ahead of the curve with Cost Curve News.

Latest News

J&J Quantifies the Impact of Its MFN Concessions: ‘It’s Hundreds of Millions of Dollars’

January 21, 2026

How Quickly Do Pharma Companies Update the Prices on Drug Websites?

January 20, 2026

Subcribe To Newsletter

Subscribe to our newsletter and stay informed about new posts and stay up-to-date on the latest news
Subscribe
© 2026 Cost Curve News | All Rights Reserved
Cost Curve NewsCost Curve News
  • Home
  • About
  • News
  • Subscribe